Strategic Review and Directorate Change
March 18 2009 - 7:54AM
UK Regulatory
TIDMOXE
RNS Number : 0585P
Oxeco PLC
18 March 2009
18 March 2009
Oxeco Plc ("Oxeco "or "the Company")
Strategic Review and Directorate Change
Investment Strategy
At the time of the Company's admission to AIM in December 2006 the Board advised
shareholders of their focus on the technology and science sectors. Since the
acquisition of Oxray Limited ("Oxray") in June 2007, the Board have focused on
seeking complementary acquisitions to Oxray in the molecular structure
determination business.
The Board has reviewed a number of investment opportunities that are in areas
complementary to the Oxray business although none were considered to offer
sufficiently attractive prospects for shareholders. It now intends to revert
to seeking opportunities within the general technology and science sectors.
The Board is reviewing its options in relation to the existing Oxray business
and will keep shareholders appraised of the ongoing strategic review.
Directorate Change
Jussi Westergren, who joined the Company at the time of the Oxray acquisition,
has today resigned as Chairman of Oxeco and the Company's Finance Director,
Michael Bretherton, has been appointed to the role as replacement Chairman.
Enquiries:
+------------------------------------+------------------------------+
| Michael Bretherton | +44 (0) 207099 7266 |
| Oxeco plc | |
| www.oxecoplc.com | |
| | |
+------------------------------------+------------------------------+
| Ray Zimmerman/Jonathan Evans | +44 (0) 207 060 1760 |
| Zimmerman Adams International | |
| Limited | |
| www.zimmint.com | |
+------------------------------------+------------------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGUUPAWUPBGGR
Oxeco (LSE:OXE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oxeco (LSE:OXE)
Historical Stock Chart
From Jul 2023 to Jul 2024
